{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=17&state=Michigan", "query": { "state": "Michigan", "city": "Detroit", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 7239, "total_pages": 724, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=18&state=Michigan&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=16&state=Michigan&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T13:50:26.064Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03040999", "title": "Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Accelerated Fractionation (AFX) Radiotherapy", "type": "RADIATION" }, { "name": "Standard Fractionation (SFX) Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 804, "start_date": "2017-04-05", "completion_date": "2024-08-21", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 24, "location_summary": "Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03040999" }, { "nct_id": "NCT00003563", "title": "Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "WBRT", "type": "RADIATION" }, { "name": "MGd", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "1998-08", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2013-10-31", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 31, "location_summary": "Greenbrae, California • Los Angeles, California • Sacramento, California + 24 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003563" }, { "nct_id": "NCT00469755", "title": "Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Adapalene Gel, 0.1%", "type": "DRUG" }, { "name": "Tazarotene Cream, 0.1%", "type": "DRUG" }, { "name": "Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "12 Years to 35 Years" }, "enrollment_count": 302, "start_date": "2006-02", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2022-07-29", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 12, "location_summary": "San Diego, California • Detroit, Michigan • Fridley, Minnesota + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Fridley", "state": "Minnesota" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00469755" }, { "nct_id": "NCT00093171", "title": "Study Evaluating rFIX; BeneFIX® in Hemophilia B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia B" ], "interventions": [ { "name": "rFIX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 23, "start_date": null, "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2009-08-21", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Detroit, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093171" }, { "nct_id": "NCT02793544", "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Lymphocytic Leukemia (CLL)", "Chemotherapy-sensitive Lymphoma", "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma", "Acute Myelogenous Leukemia (AML)", "Acute Biphenotypic Leukemia (ABL)", "Acute Undifferentiated Leukemia (AUL)" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy on Day -1", "type": "RADIATION" }, { "name": "Infusion of non-T-cell depleted bone marrow on Day 0", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1", "type": "RADIATION" }, { "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -6 and -5", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -2 and -1", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -5 and -4", "type": "DRUG" }, { "name": "Post-HCT Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2016-12", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 11, "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793544" }, { "nct_id": "NCT02054793", "title": "Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Itraconazole", "type": "DRUG" }, { "name": "Orteronel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emmanuel Antonarakis, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2014-06", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2014-07-23", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Detroit, Michigan", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02054793" }, { "nct_id": "NCT02257684", "title": "A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "pegcrisantaspase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 4, "start_date": "2014-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257684" }, { "nct_id": "NCT02817633", "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "TSR-022", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "TSR-042", "type": "DRUG" }, { "name": "TSR-033", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 463, "start_date": "2016-07-08", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 64, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02817633" }, { "nct_id": "NCT05508906", "title": "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "ER-positive Breast Cancer", "HER2-negative Breast Cancer", "Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Palazestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Alpelisib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Atirmociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2022-08-31", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 14, "location_summary": "Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05508906" }, { "nct_id": "NCT02200133", "title": "Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT" ], "interventions": [ { "name": "Individualized Survivorship Care Plan (SCP)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 495, "start_date": "2015-04", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-09-07", "last_synced_at": "2026-10-29T13:50:26.064Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Gainesville, Florida • Maywood, Illinois + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02200133" } ] }